Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome

Journal of Clinical Virology

Volumn 53, Issue 4, 2012, Pages 297-301

  Tedeschi, Rosamaria ^a   Bortolin, Maria Teresa ^a   Bidoli, Ettore ^a   Zanussi, Stefania ^a   Pratesi, Chiara ^a   Vaccher, Emanuela ^a   Tirelli, Umberto ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CD4; CD8; EBV; HIV; NHL; Viral load

Indexed keywords

ANTINEOPLASTIC AGENT; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84858151900     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.021     Document Type: Article

References (28)

1. Silvestris N., Crucitta E., Lorusso V., Gamucci T., De Lena M. AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies. Int J Oncol 2002, 20(3):611-615.
2. Pluda J.M., Venzon D.J., Tosato G., Lietzau J., Wyvill K., Nelson D.L., et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11(6):1099-1107.
3. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol 2002, 33(4):392-404.
4. International Agency for Research on Cancer Epstein Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8 1997, International Agency for Research on Cancer, Lyon, France.
5. Park S., Lee J., Ko Y.H., Han A., Jun H.J., Lee S.C., et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007, 110(3):972-978.
6. Paydas S., Ergin M., Erdogan S., Seydaoglu G. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res 2008, 32(9):1424-1430.
7. Dehee A., Asselot C., Piolot T., Jacomet C., Rozenbaum W., Vidaud M., et al. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 2001, 65(3):543-552.
8. Fan H., Kim S.C., Chima C.O., Israel B.F., Lawless K.M., Eagan P.A., et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005, 75(1):59-69.
9. Bonnet F., Jouvencel A.C., Parrens M., Leon M.J., Cotto E., Garrigue I., et al. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 2006, 36(4):258-263.
10. Lin L., Lee J.Y., Kaplan L.D., Dezube B.J., Noy A., Krown S.E., et al. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 2009, 27(15):2496-2502.
11. Katano H., Sato Y., Hoshino S., Tachikawa N., Oka S., Morishita Y., et al. Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient. Microbes Infect 2007, 9(14-15):1581-1589.
12. Kostrikis L.G., Touloumi G., Karanicolas R., Pantazis N., Anastassopoulou C., Karafoulidou A., et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002, 76(20):10099-10108.
13. Bortolin M.T., Zanussi S., Talamini R., Simonelli C., Pratesi C., Tedeschi R., et al. Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses 2010, 26(2):245-251.
14. Tirelli U., Spina M., Gaidano G., Vaccher E., Franceschi S., Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000, 14:1675.
15. Vaccher E., Spina M., di Gennaro G., Talamini R., Nasti G., Schioppa O., et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001, 91(1):155-163.
16. Spina M., Jager U., Sparano J.A., Talamini R., Simonelli C., Michieli M., et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005, 105(5):1891-1897.
17. Mounier N., Spina M., Gabarre J., Raphael M., Rizzardini G., Golfier J.B., et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006, 107(10):3832-3840.
18. Bortolin M.T., Pratesi C., Dolcetti R., Bidoli E., Vaccher E., Zanussi S., et al. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 2006, 233(2):247-254.
19. Tedeschi R., Enbom M., Bidoli E., Linde A., De Paoli P., Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001, 39(12):4269-4273.
20. Viard J.P., Burgard M., Hubert J.B., Aaron L., Rabian C., Pertuiset N., et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004, 18(1):45-49.
21. Lim S.T., Karim R., Tulpule A., Nathwani B.N., Levine A.M. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005, 23(33):8477-8482.
22. Simcock M., Blasko M., Karrer U., Bertisch B., Pless M., Blumer L., et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007, 12(6):931-939.
23. Miralles P., Berenguer J., Ribera J.M., Rubio R., Mahillo B., Téllez M.J., et al. Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas, Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr 2007, 44(2):167-173.
24. Wood C., Harrington W.J. AIDS and associated malignancies. Cell Res 2005, 15:947-952.
25. Boshoff C., Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002, 2:373-382.
26. Van Baarle D., Wolthers K.C., Hovenkamp E., Niesters H.G., Osterhaus A.D., Miedema F., et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002, 186(3):405-409.
27. Chan K.C., Zhang J., Chan A.T., Lei K.I., Leung S.F., Chan L.Y., et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003, 63(9):2028-2032.
28. Beachler D.C., Gellert L.L., Jacobson L.P., Ambinder R.F., Breen E.C., Martínez-Maza O., et al. Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma risk. J Acquir Immune Defic Syndr 2011, 56(2):188-192.